Atjaunināt sīkdatņu piekrišanu

E-grāmata: Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies: Proceedings of a Workshop

  • Formāts: 124 pages
  • Izdošanas datums: 29-Dec-2017
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309466486
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 3,93 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 124 pages
  • Izdošanas datums: 29-Dec-2017
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309466486
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

On June 26, 2017, the Forum on Regenerative Medicine hosted a public workshop in Washington, DC, titled Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies in order to examine and discuss the challenges, opportunities, and best practices associated with defining and measuring the quality of cell and tissue products and raw materials in the research and manufacturing of regenerative medicine therapies. The goal of the workshop was to learn from existing examples of the manufacturing of early-generation regenerative medicine products and to address how progress could be made in identifying and measuring critical quality attributes. The workshop also addressed the challenges of designing and adhering to standards as a way of helping those who are working to scale up processes and techniques from a research laboratory to the manufacturing environment. This publication summarizes the presentations and discussions from the workshop.

Table of Contents



Front Matter 1 Introduction 2 Transitioning from Discovery and Development to Manufacturing 3 Identifying and Measuring Critical Quality Attributes 4 Designing Technologies to Meet the Manufacturing Needs of New Regenerative Medicine Therapies 5 Considerations for Improving and Regulating Regenerative Medicine Products 6 Potential Next Steps for Supporting the Development, Manufacture, and Regulation of Regenerative Medicine Therapies References Appendix A: Workshop Agenda Appendix B: Speaker Biographical Sketches Appendix C: Statement of Task Appendix D: Registered Attendees
Acronyms and Abbreviations xix
1 Introduction
1(6)
Overview of the Workshop
3(3)
Organization of the Proceedings of a Workshop
6(1)
2 Transitioning From Discovery And Development To Manufacturing
7(18)
Key Challenges Facing the Regenerative Medicine Industry as Safe and Effective Therapies Are Developed for Patients
8(5)
Transitioning Engineered T Cells from Discovery to Manufacturing and Regulatory Approval
13(3)
Learning from Past Experiences in Vascular Engineering
16(2)
Getting to the Factory of the Future
18(2)
Discussion
20(5)
3 Identifying And Measuring Critical Quality Attributes
25(16)
Achieving Confidence in Measurements for Regenerative Medicine Products
26(3)
Possible Opportunities and Challenges for Determining Critical Quality Attributes in Early-Phase Clinical Trials
29(4)
A Commercial Perspective on Building Product Attributes
33(4)
Discussion
37(4)
4 Designing Technologies To Meet The Manufacturing Needs Of New Regenerative Medicine Therapies
41(14)
Models for Manufacturing Cell Therapy Products
42(3)
The Role of Automation in Manufacturing
45(3)
Scaling Personalized Cell Therapy Manufacturing
48(3)
Discussion
51(4)
5 Considerations For Improving And Regulating Regenerative Medicine Products
55(12)
Improving Stem Cell-Based Products: Perspectives from a Patient-Centric Research Organization
56(2)
Strategies to Improve Characterization of Stem Cell-Based Products
58(3)
Regulatory Implications for Development and Global Manufacturing of Regenerative Medicine Products
61(2)
Discussion
63(4)
6 Potential Next Steps For Supporting The Development, Manufacture, And Regulation Of Regenerative Medicine Therapies
67(14)
Fostering Innovation and Collaboration: An Interdisciplinary Approach to Regenerative Medicine
67(3)
Reflections and Take-Away Messages from the Workshop
70(5)
Final Thoughts
75(2)
References
77(4)
Appendixes
A Workshop Agenda
81(8)
B Speaker Biographical Sketches
89(8)
C Statement Of Task
97(2)
D Registered Attendees
99